此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Collection of Venous and Capillary Blood Samples Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)

2026年11月12日 更新者:LumiraDx UK Limited

Cobas® Lumira 静脉和毛细血管血样采集用于新型诊断设备的研究、优化和校准 (EVOLVE)

This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira instrument. This instrument is a diagnostic medical device with single-use test strips, that allows diagnostic testing right at the patient's side. The aim is to improve doctors' ability to monitor health conditions more quickly and easily.

Approximately 30,000 patients are expected to participate in this study, across multiple UK sites.

研究概览

详细说明

This prospective, multicenter sample collection study will involve the collection of venous and capillary blood samples from approximately 12,000 participants across the 8 study cohorts A-H. The EVOLVE study will be conducted at study sites in the United Kingdom (UK). Collected samples may be tested at the study sites and at the in-house laboratory at LumiraDx UK Ltd (hereafter referred to as 'LumiraDx UK'. LumiraDx UK is a member of the Roche Group.) on the cobas® lumira platform using the cobas® lumira Test Strip.

Venous samples also will be sent to LumiraDx UK and/or Roche Germany for testing on a reference method. Participants presenting to medical units (including but not limited to A&E departments, hospital ward, or outpatient clinics) with signs and symptoms of diseases related to but not limited to embolism, infection, inflammation, cardiovascular, renal conditions, metabolic disorders, oral anticoagulant therapy, hypercholesterolemia, and hepatic disorder will be enrolled. Participants will be assigned to a study cohort based on primary presenting condition at the time of enrollment.

研究类型

观察性的

注册 (估计的)

12000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Glasgow、英国、G81 4HX
        • 招聘中
        • Golden Jubilee National Hospital
        • 接触:
        • 首席研究员:
          • Roy Gardner, MBChB MD MRCP FESC FHFA FACC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

16年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

UK-based adults presenting to a study site and meeting the eligibility criteria. There are no demographic requirements for this study

描述

Inclusion Criteria:

  1. Willing and able to provide written informed consent.

  2. Willing to comply with study procedures.

  3. The participant must present as one of the following cohorts (primary presenting condition):

    • Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)
    • Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)
    • Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)
    • Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)
    • Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)
    • Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)
    • Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )
    • Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).

Inclusion Criteria for Cohorts A, B, C, D, E, G, and H:

1. Participants ≥ 18 years of age

Inclusion Criteria for Cohort F (Diabetes Cohort):

1. Participants ≥ 16 years old

Exclusion Criteria:

  1. Subjects deemed inappropriate for the study by the Principal Investigator.
  2. Participants who have previously been enrolled in the EVOLVE study in the past 60 days.

Exclusion Criteria for Cohort E (Oral Anticoagulation Cohort):

  1. Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.
  2. Subjects who have anti-phospholipid antibody syndrome (APS)
  3. The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:CROSS_SECTIONAL

队列和干预

团体/队列
干预/治疗
Blood clot

participants presenting with symptoms indicative of thromboembolic events

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

Infection/Inflammation

participants presenting with symptoms indicative of infection or inflammatory disorders

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

Heart disease

participants presenting with symptoms indicative of heart failure or acute coronary syndrome

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

Kidney disease

participants presenting with symptoms indicative of renal disorders

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

Blood thinners

participants with ongoing vitamin K antagonist therapy for at least four weeks

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

Diabetes

participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

High cholesterol

participants presenting with symptoms indicative of Hypercholesterolemia

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

Liver disease

participants with symptoms indicative of hepatic disorders

Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Biomarker concentration
大体时间:Baseline

Blood samples will be used to take a quantitative baseline measurement of 1 or more biomarkers associated with the following health conditions:

  • Thromboembolism
  • Infection/Inflammation
  • Cardiovascular disease
  • Kidney disease
  • Vitamin K antagonist therapy
  • Diabetes
  • Hypercholesterolemia
  • Liver disease.

Measurements are used for research, development and calibration of point-of-care diagnostic tests, and may compare results between different test methods. There is no statistical analysis planned on these measurements.

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Roy S Gardner, MBChB, MD、Golden Jubilee National Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月24日

初级完成 (估计的)

2028年4月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2026年1月14日

首先提交符合 QC 标准的

2026年1月22日

首次发布 (实际的)

2026年1月30日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅